1. Introduction
===============

Hepatitis C virus (HCV) is a major cause of chronic hepatitis responsible for more \>185 million worldwide accounting a seroprevalence of 2.8%.^\[[@R1]--[@R3]\]^ Although the incidence rate of HCV infection is decreasing in the developed countries, deaths from liver disease secondary to HCV infection will continue to increase over the next 20 years.^\[[@R4]\]^

In low- and middle-income countries, interferon and ribavirin (RBV)-based therapies are the first choices due to their availability and low cost. The combination of RBV and pegylated-interferon-alpha was considered the standard treatment for HCV infection in the last decade where those infected by genotypes 1 and 4 are treated for 48 weeks, and those infected by genotypes 2 and 3 are treated for 24 weeks.^\[[@R5]\]^ Recently, the use of direct-acting antivirals has proven effective against HCV in developed countries, significantly decreasing morbidity and mortality. However, low- and middle-income countries, most of which are highly endemic areas, access to new antiviral drugs still is restricted due to high cost.^\[[@R6]\]^

Several predictors of successful treatment of chronic hepatitis C (CHC) using interferon and RBV have been identified,^\[[@R7],[@R8]\]^ such as factors related to the virus (infection by HCV genotype 2--3, basal HCV viral load, and HCV genetic variability) or to the host (liver inflammation, fibrosis, lower serum cholesterol values and interleukin 28B polymorphisms C/C, and vitamin D concentration).^\[[@R9]--[@R11]\]^

Calcitriol is an important modulator in the immune pathways and is also known to be involved in cell proliferation and differentiation.^\[[@R12]\]^ Most of its biological effects are mediated through the vitamin D receptor (VDR), a member of the nuclear receptor superfamily of ligand-activated transcription factors^\[[@R13]--[@R15]\]^ and directed to these cells connected with a binding protein. Carrier globulin/binding protein (GC)-globulin is the main serum vitamin D binding protein; it is polymorphic and characterized in Caucasian populations by a great variability at 2 loci (rs7041 and rs4588).^\[[@R16]\]^

The presence of the minor alleles in GC-globulin loci has been associated with lower circulating vitamin D levels,^\[[@R17]\]^ instead VDR polymorphisms has been associated with rapid fibrosis progression (haplotype bAt\[CCA\]).^\[[@R18]\]^ Vitamin D deficiency has been associated to low sustained virological response (SVR) among hepatitis C patients.^\[[@R19],[@R20]\]^ Moreover, vitamin D levels and single nucleotide polymorphisms (SNPs) involved in its metabolism have been related to anti-HCV therapy response.^\[[@R21]--[@R23]\]^ In this way, our aim is to evaluate the influence of genetic determinants of 25-hydroxyvitamin D (25 (OH)D) serum levels and the association with demographic, metabolic, and virological data in chronic HCV patients living in South America.

2. Methods
==========

2.1. Study design and population
--------------------------------

This is an observational study that included 148 CHC patients resident in Rio de Janeiro recruited at Viral Hepatitis Ambulatory (Viral Hepatitis Laboratory, Oswaldo Cruz Institute, FIOCRUZ), Hepatology Unit (Clementino Fraga Filho University Hospital, UFRJ), General Medicine Department (Gaffrée Guinle University Hospital, UNIRIO), and Hepatology Unit (Antonio Pedro University Hospital, UFF). Nonprobabilistic recruitment was conducted from 2011 to 2012 year.

Patients were included if they had a virological diagnosis of CHC (anti-HCV and HCV-RNA reactive serum sample, with persistently abnormal alanine aminotransferase \[ALT\], at least 6 months) and more than 18 years of age. The infecting HCV genotypes were the following: 1, 2, 3, and 5. Patients were excluded if they were positive for serum hepatitis B surface antigen or antihuman immunodeficiency virus antibody, or exhibited other causes of hepatocellular injury (eg, any history of alcoholism, autoimmune hepatitis, advanced cirrhosis, or treatment with hepatotoxic drugs), and concomitant use of drugs known to affect serum vitamin D concentration and intravenous drug use. These factors were excluded due to potential source of bias.

This study was approved by the Ethics Committee of FIOCRUZ (CAAE 41269015.3.0000.5248). Informed consent was obtained from each patient who was included in the study, and the study protocol was followed according to the ethical guidelines of the 1975 Declaration of Helsinki.

2.2. Clinical and laboratorial data
-----------------------------------

All serum samples were tested for anti-HCV using commercial EIA kit HCV Ab (Radim, Pomezia, Italy), where all anti-HCV-reactive samples were retested in duplicate.

HCV RNA viral load was determined using CobasTaqMan HCV Test (Roche Molecular Systems, Inc, Basel, Switzerland) or Abbott Real T*ime* HCV m2000sp (Abbott Laboratories, IL) and expressed as IU/mL. HCV genotyping was performed using INNO-LIPA HCV II kit (Innogenetics, Zwijnaarden, Belgium) or Abbott Real T*ime* HCV m2000sp (Abbott Laboratories) according to manufacturer\'s instruction.

Clinical and demographic data were collected simultaneously from all patients. A 12-hour overnight fasting blood sample was draw to determine serum levels of ALT, gamma-glutamyltransferase (GGT), total cholesterol (Tc), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, plasma glucose concentration, and platelet count.

Baseline serum vitamin D level was assessed by measuring serum 25 (OH)D levels using automated immunochemiluminometric assay (ICMA) (Liason 25 (OH) Vitamin D, Diasorin, Varceli, Italy) with 20 ng/mL being considered the threshold value. Serum insulin was also determined using ICMA (Liason Insulin Assay, Diasorin, Varceli, Italy). Insulin resistance was determined using homeostasis model assessment method (HOMA ≥2).^\[[@R24]\]^

Hepatic fibrosis was assessed using Fib-4 and Forns index as the same as described previously.^\[[@R25]\]^ When Fib-4 was less than 1.45, individual was considered as low fibrosis, and if Fib-4 was ≥1.45, Forns index was considered. Forns index below 4.2 was considered as low fibrosis, and index above or equal to 4.2 was considered high fibrosis.^\[[@R25]\]^

Genomic DNA was obtained from whole blood samples using QIamp DNA Mini Kit (Quiagen, Valencia, CA). The purified and elute DNA was quantified using a Nanodrop Spectrophotometer ND-1000 (Thermo Scientific, Rockford, IL). Thereafter, DNA was diluted in UltraPure DNase/RNase-Free water (Invitrogen Corporation, Camarillo, CA) to a concentration of 2 ng. The allelic discrimination analysis was performed using the TaqMan assays (Applied Biosystems, Foster City, CA) at ViiA7 Real-Time PCR System 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). TaqMan Master mix (2.5 μL), TaqMan assay (0.25 μL), and H~2~O (1.25 μL) were added to a final volume of 4 μL per sample, and 1 μL of DNA was added for a total reaction volume of 5 μL. Reaction conditions for SNPs ApaI, FokI, TaqI, and rs4588 were: 10 minutes at 95 °C after 50 cycles of denaturation at 95 °C (15 seconds) and annealing at 60 °C (1 minute). To genotyping SNPs BsmI and rs7041 TaqMan Master mix (5.0 μL), TaqMan assay (0.50 μL), and H~2~O (3.5 μL) were added to a final volume of 9 μL per sample, and 1 μLof DNA was added for a total reaction volume of 10 μL. Reaction conditions for these polymorphisms were: 10 minutes at 95 °C after 50 cycles of denaturation at 95 °C (15 seconds) and annealing at 60 °C (1 minute) to BsmI and 61 °C (1 minute) to rs7041.^\[[@R26]\]^

We selected tag-SNPs from vitamin D metabolism-related genes, VDR and GC, and the haplotype bAt \[CCA\]. These SNPs were chosen using previous literature information.^\[[@R18],[@R19],[@R26]--[@R28]\]^ Public databases were used to collect additional information about SNPs and genes: NCBI [http://www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/).

The analyzed SNPs were: VDR-*rs7975232 (ApaI) C\>A*, *rs731236 A\>G (TaqI)*, *rs1544410 C\>T (BsmI)*, *rs10735810 T\>C (FokI)* and GC-*rs4588* and *rs7041.* According to Pubmed Database, the frequencies were: GC (rs7041): A = 0.4841/58741 (ExAC) C = 0.3816/1911 (1000 Genomes); GC (rs4588): T = 0.2528/30670 (ExAC) T = 0.2079/1041 (1000 Genomes); BsmI rs1544410: T = 0.2959/1482 (1000 Genomes); ApaI (rs7975232): C = 0.4813/58108 (ExAC) C = 0.4846/2427 (1000 Genomes); TaqI (rs731236): G = 0.3338/40509 (ExAC) G = 0.2766/1385 (1000 Genomes); and FokI (rs10735810): A = 0.3285/1645.

Haplotypes were constructed from the combination of the VDR polymorphisms BsmI, ApaI, and TaqI {bAt \[CCA\] \["b" (BsmI allele C), "A" (ApaI allele C), and "t" (TaqI allele A)\]} and their frequencies were inferred using the PHASE 2.1.1 program (Matthew Stephens Lab, University of Chicago). To predict both allele frequencies will remain constant because they are in equilibrium, we calculated the Hardy--Weinberg equilibrium by X^2^ (*P* \< .05).

2.3. Statistical analysis
-------------------------

Continuous data are expressed as mean ± standard deviation, and the categorical data are expressed as number (percentage). Comparisons of differences in categorical date between groups were performed using the Chi-square test. Distributions of continuous variables were analyzed by the Student *t* test or Mann--Whitney *U* test for the 2 groups where appropriate. Missing data were presented in tables when appropriate. Independent factors possibly affecting 25 (OH)D concentration (cut off value of 20 ng/mL) were determined by stepwise multiple logistic regression analysis.

Hardy--Weinberg equilibrium for each SNP was compared using the Pearson chi-square test (X^2^). 25 (OH)D concentration and the variance in each genotype was accessed in one-way ANOVA with Bonferroni correction. At univariate analyses, *P*-value were considered significant when *P*�\<�.2 and in multivariate analyze *P*�\<�.05. All the tests were performed with IBM SPSS Statistics 20.0 for Windows (Chicago, IL).

3. Results
==========

3.1. Baseline characteristics
-----------------------------

Demographic, virological, and clinical features of population studied are shown in Table [1](#T1){ref-type="table"}. There were 56 men and 92 women, with mean age of 54.41 (±11.27). Elevated mean of ALT, AST, phosphatase, GGT, blood glucose, Tc, and LDL serum levels were observed in patients.

###### 

Demographic, laboratory, and metabolic data of 148 chronic hepatitis patients (CHC).
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Normal median values were observed for: very-low-density lipoprotein (VLDL) cholesterol (19.82 ± 10.83 mg/dL), HDL (54.80 ± 20.86 mg/dL), platelets (20,479.70492 ± 60,563.37103/mm), hematocrit (40.64% ± 6.48%), and hemoglobin (13.64 ± 1.78 ng/mL) (anemic classification: hemoglobin values \<12 ng/mL for women and \<13 ng/mL for men). Using the cutoff value of 20 ng/mL, 82/148 (54.40%) patients demonstrated deficiency of vitamin D. HCV RNA viral load (log mean) was high and most prevalent genotype was 1 (88.37%). During this study, 68 CHC patients were treated for HCV using pegylated-interferon and RBV and in this subgroup, 46 (31.08%) did not achieve SVR. Sixty-eight patients (45.94%) were not treated for HCV. Using fibrosis algorithm, 52.00% (n = 77) presented high level. The HOMA index mean was also lower than the cutoff established in this work (1.99 ± 3.33), where 33.10% (n = 49) presented insulin resistance.

3.2. Association between serum 25 (OH)D levels, clinical and viral data in chronic HCV patients
-----------------------------------------------------------------------------------------------

To assess the relationship among 25 (OH)D concentration and demographic and laboratory data in HCV patients, a cutoff value was established (deficiency \<20 ng/mL). High mean values of age (*P* = .042), AST (*P* = .022), HDL (*P* = .072), triglycerides (0.047), SVR (*P* = .108), and presence of high fibrosis (*P* = .016) were associated to 25 (OH)D deficiency at univariate analysis.

Patients with high rates of platelets presented 25 (OH)D ≥20 ng/mL (*P* = .014), as also blood glucose (*P* = .106) and ALT (*P* = .160) were high in patients with 25 (OH)D ≥20 ng/mL (Table [2](#T2){ref-type="table"}). At multiple linear regression analysis, AST (*P* = .019 \[CI: 1.003--1.034\]), Tc (*P* = .038 \[CI: 1.004--1.164\]), and fibrosis grade (*P* \< .001 \[CI: 0.000--0.844\]) were significant.

###### 

Univariate and multivariate regression analysis of factors associated with 25 (OH) concentration.
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3.3. Association between VDR and GC polymorphism according to 25 (OH)D level among HCV patients
-----------------------------------------------------------------------------------------------

To study the implication of these SNPs and 25 (OH)D concentration according to clinical and laboratory data of HCV patients, first our sample was categorized according to previously defined cutoff value (25 (OH)D deficiency \< 20 ng/mL). Second, the alleles were categorized in risk allele/nonrisk allele and grouped, and presence/absence of haplotype bAt \[CCA\]. The genotype distribution of all investigated SNPs was in Hardy--Weinberg equilibrium. Only FokI was statistically significant (*P* = .028), where allele T were associated with 25 (OH)D ≥20 ng/mL.

After this, the one-way ANOVA test with Bonferroni multiple comparison posttest (*P* \< .05) was done. There was no statistically difference between SNPs genotypes and 25 (OH)D concentration in 148 Brazilian CHC patients (Fig. [1](#F1){ref-type="fig"}). ApaI: (CC vs CA \[t = 0.172\], CC vs AA \[t = 0.199\], CA vs AA \[t = 0.430\]); TaqI: (AA vs AG \[t = 0.806\], AA vs GG \[t = 0.990\], AG vs GG \[t = 0.497\]); BsmI: (CC vs CT \[t = 1.281\], CC vs TT \[t = 0.564\], CT vs TT \[t = 0.278\]); FokI: (CC vs CT \[t = 1.786\], CC vs TT \[t = 0.961\], CT vs TT \[t = 2.040\]); GC rs4588: (AA vs AC \[t = 0.927\], AA vs CC \[t = 0.101\], AC vs CC \[t = 1.515\]); GC rs7041: (TT vs TG \[t = 0.610\], TT vs GG \[t = 2.001\], TG vs GG \[t = 1.565\]).

![Association of VDR and GC gene polymorphism with 25 (OH)D concentration in Brazilian chronic HCV patients. No significant variance was found using ANOVA I test with Bonferroni correction (*P* \< .05). GC = carrier globulin/binding protein, HCV = hepatitis C virus, 25 (OH)D = 25-hydroxyvitamin D, VDR = vitamin D receptor.](medi-97-e9881-g003){#F1}

Besides that we carried out a bivariate and a linear regression analysis by comparing favorable allele group with demographic, biochemical, and viral data. The significant results are given in Table [3](#T3){ref-type="table"}. In the multivariate analysis, using SPNs as dependent variable, we found association between BsmIrs1544410 (fibrosis algorithm), TaqI rs731236 (triglycerides and fibrosis algorithm), FokI rs10735810 (HDL), GC rs4588 (treated and none-treated, and GGT), and GC rs7041 (genotype 1 and none-1).

###### 

Univariate and multivariate regression analysis of factors associated with VDR-ApaI rs7975232, TaqI rs731236, BsmI rs1544410, FokIrs10735810, GC-rs4588, and GC-rs7041 SNPs.
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4. Discussion
=============

In vitamin D pathway, a series of studies had reported on interaction between vitamin D-related genes and 25 (OH)D levels. Among them, VDR and vitamin D-binding protein (DBP) genes played an important role in vitamin D pathway. Previous studies had shown that genetic variations in these genes had a significant effect on vitamin D levels in many populations including the Chinese,^\[[@R29],[@R30]\]^ Japanese,^\[[@R31]\]^ Caucasian,^\[[@R16],[@R17],[@R19],[@R20],[@R27]\]^ Brazilian healthy girls,^\[[@R26]\]^ and in this study, FokI C allele in Brazilian CHC patients were associated to 25 (OH)D \<20 ng/mL.

This way, we hypothesized that genetic determinants of 25 (OH)D serum levels may be associated with demographic, metabolic, and virological data in chronic HCV Brazilian patients. To our knowledge, this is the first study that describes the interaction between vitamin D-related genes and 25 (OH)D levels among HCV-infected patients from South America giving some new insight about these parameters in tropical regions.

In this study, the prevalence of vitamin D deficiency was 55.04% that is lower than previously observed in similar population in Brazil (63%)^\[[@R25]\]^ and among Italians HCV patients (73%).^\[[@R20],[@R22],[@R23],[@R32]\]^ Moreover, severe fibrosis was found in patients with lower vitamin D concentration (Table [2](#T2){ref-type="table"}). Lange et al^\[[@R19]\]^ also found that the prevalence of vitamin D deficiency was greater in HCV patients with more advanced fibrosis.

In the present study, Fib-4 and Forns index were used to determine fibrosis level since they are useful for predicting fibrosis grade in the absence of biopsy.^\[[@R33],[@R34]\]^ Forns index can be used to differentiate patients with mild (F0--F1) fibrosis from those with severe (F2--F4) fibrosis demonstrating diagnostic performance of AUROC 0.76 to 0.79 for the detection of significant fibrosis. FIB-4 index correctly identified patients with severe fibrosis (F3--F4) and cirrhosis with an AUROC of 0.85 and 0.91, respectively. An FIB-4 index \<1.45 had a negative predictive value of 94.7% to exclude severe fibrosis and a sensitivity of 74.3%. An FIB-4 index higher than 3.25 had a positive predictive value of 82.1% for the confirmation of significant fibrosis (F3--F4), with a specificity of 98.2%.^\[[@R35],[@R36]\]^

Vitamin D deficiency is common among patients with liver diseases. Whether vitamin D status can also affect liver function is poorly understood. In this study, low 25 (OH)D concentration was associated with high AST and cholesterol total value. Skaaby et al^\[[@R37]\]^ investigate the association between vitamin D status, liver enzymes, and incident liver disease in 2649 individuals and found that the risk of having a high level of ALT, AST, or GGT tended to be higher for lower vitamin D levels, in accordance with our results.

There is conflicting information when it comes to the link between cholesterol and vitamin D levels. Population studies show that people with lower vitamin D levels are more likely to have high cholesterol, although this does not prove a cause and effect relationship despite being according our findings.^\[[@R38]\]^ To the National Institutes of Health, there is insufficient evidence to determine any relationship between vitamin D intake and cholesterol levels.

It was not found an association between vitamin D levels and HCV RNA mean values. Conversely, Gerova et al^\[[@R39]\]^ found an inverse relationship between 25 (OH)D and HCV-RNA levels in Bulgarian HCV patients. These differences could be due to variation in the 25 (OH)D assay used, vitamin D cutoff, and the different ethnicities and geographic latitude of populations studied, and clinical trials.

A strong association of vitamin D sufficiency to TT genotype in FokI was found. This way, FokI C\>T polymorphisms may be used as a molecular marker to predict the risk and to evaluate the disease severity of HCC in those infected with HCV since low concentrations of vitamin D is directly associated with increased liver injury in Brazilian population. Differently, Shehab et al^\[[@R40]\]^ observed that VDR genetic polymorphisms are significantly associated with the occurrence of HCV-related HCC especially T allele carriers which could be considered as a risk factor of hepatocellular carcinoma in Egyptian patients.

Regarding VDR and DBP genes polymorphisms in Brazilian population, the BsmI, ApaI, TaqI, and the rs4588 and rs7041 polymorphisms were most consistently associated with lower 25 (OH)D levels.^\[[@R26],[@R40]\]^ However, in the present study both SNPs were not associated with lower levels of 25 (OH)D after applying Bonferroni correction. Nevertheless, Falleti et al^\[[@R16]\]^ demonstrated that normal serum vitamin D levels and the carriage of GC-globulin WT isoform strongly predict the achievement of SVR after PEG-interferon plus RBV antiviral therapy. Some studies found that the carriage of ApaI CC genotype and TaqI AA genotype had significant higher viral load as compared to those with ApaI CA/AA type and TaqI AG type, respectively.^\[[@R28]\]^ Besides that, VDR gene variants can modulate biological effects of vitamin D without influencing serum vitamin D levels.^\[[@R15],[@R41]\]^

Some variables could explain these differences. It is well established that there are racial differences in the relations between the 25 (OH)D concentrations, parathyroid hormone concentration, and calcium homeostasis.^\[[@R14]\]^ Racial differences in vitamin D physiology or race-specific factors that modify the effects of vitamin D may affect the immune response to HCV.^\[[@R42]\]^

We did not find a significant association between VDR bAt \[CCA\] haplotype and clinical and laboratory data in HCV patients as the same as Hung et al^\[[@R28]\]^ who also did not find any relationship between this haplotype and response to peginterferon plus RBV therapy. These genetic variations have been described as important modulators of several chronic liver diseases such as primary biliary cirrhosis and autoimmune hepatitis.^\[[@R43]\]^

In the present study, fibrosis was associated to BsmI rs1544410 and TaqI rs731236 what was not observed among Chinese population with chronic HCV infection.^\[[@R28]\]^ To explain the relation between high serum triglycerides and the effect of TaqI rs731236, a hypothetical explanation is related to the mechanism in which vitamin D induces the expression of VLDL-cholesterol receptors in some types of cell.^\[[@R44]\]^ This situation is associated with an elevation of the levels of VLDL and triglycerides and is common in CHC patients.^\[[@R45]\]^ The relationship between HCV genotype and GC remains unknown.

This study presents some limitations, like the absence of race information or ancestry profile, sun exposure, and season of collection that could create some bias regarding vitamin D measures.

In conclusion, the present study suggests a significant association of VDR FokI rs10735810 and the 25 (OH)D concentration in CHC patients, strong association between fibrosis algorithm, 25 (OH)D, BsmI rs15444, and TaqI rs731236, and finally the association between GC rs7041 (Genotype 1/ None-1). These data could provide helpful information for understanding the complex mechanisms underlying the virus--host interaction and the variations observed in antiviral therapy responses.
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